Showing 801-810 of 4009 results for "".
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
https://reachmd.com/programs/cme/ttr-levels-and-associated-disease-risk-insights-from-2025-pns-conference/36192/Review recent data from the UK Biobank showing the increased risk of vascular and cognitive comorbidities associated with naturally low transthyretin levels.Redefining Women’s Sexual Wellness and Aesthetics
https://reachmd.com/ma-issues-index/september-october-2025/redefining-womens-sexual-wellness-and-aesthetics/39259/The end of medical gaslightingPerspectives on Proton Beam Therapy: Benefits, Challenges, & Results
https://reachmd.com/programs/advanced-treatments-innovations-mayo-clinic/perspectives-proton-beam-therapy-benefits-challenges-results/11154/As the use of proton beam therapy continues to grow for cancer treatment, it’s time we take a look at some of its benefits and challenges.HIPEC: A Novel Treatment for Advanced Abdominal Cancers
https://reachmd.com/programs/advanced-treatments-innovations-mayo-clinic/hipec-novel-treatment-advanced-abdominal-cancers/11175/For cancers within the abdomen, a cure is rare because it’s hard to get chemotherapy to reach those areas. But that’s not the case with HIPEC.Leveraging CGM to Its Full Potential in People with T2D
https://reachmd.com/programs/cme/cgm-full-potential-t2d/50980/Continuous glucose monitoring (CGM) has been widely used in individuals with type 1 diabetes (T1D), and evolving guidelines increasingly recommend its use for those with type 2 diabetes (T2D) as well. However, despite these updated recommendations, real-world adoption to support T2D management has rDKA in Focus: What the New Consensus Means for Practice
https://reachmd.com/programs/cme/dka-new-consensus-practice/50979/If widespread use of continuous ketone monitoring (CKM) devices is to be safe and effective in reducing the occurrence of diabetic ketoacidosis (DKA), it is important to establish clear ketone thresholds which notify CKM users when action on their part is required. In preparation for availability anPruritus In PN and AD: Challenge How You Manage Itch
https://reachmd.com/programs/cme/pruritus-in-pn-and-ad-challenge-how-you-manage-itch/36304/Use validated assessment tools to prioritize and measure itch in prurigo nodularis and atopic dermatitis in an interactive CME escape room.DKA in the Real World: Evidence and Cases that Matter
https://reachmd.com/programs/cme/dka-real-world-evidence-cases/50981/Recently, an international panel of experts developed objective practical recommendations on how continuous ketone monitoring could improve diabetes care. Even more recently, new data was presented on the prevalence, risk, burden, and management of DKA. Join worldwide experts as they discuss the praTreatment of Developmental/Epileptic Encephalopathy With Spike-Wave Activation in Sleep
https://reachmd.com/diseases-diagnoses/epilepsy-seizures/treatment-of-developmentalepileptic-encephalopathy-with-spike-wave-activation-in-sleep/39968/Developmental/epileptic encephalopathy with spike-wave activation in sleep is a unique electroclinical entity accompanied by cognitive, developmental, or behavioral stagnation or regression.Pharmacology of Emerging Selective Sodium Channel Antagonists for the Treatment of Epilepsy
https://reachmd.com/diseases-diagnoses/epilepsy-seizures/pharmacology-of-emerging-selective-sodium-channel-antagonists-for-the-treatment-of-epilepsy/39904/The development of isoform-selective sodium channel inhibitors that spare GABAergic interneuron function is in its early stages but holds promise as an exciting area of research.